NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$119.4b

Last Updated

2021/09/18 10:01 UTC

Data Sources

Company Financials +

Executive Summary

Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More Details


Snowflake Analysis

Outstanding track record with adequate balance sheet.

Share Price & News

How has Sino Biopharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1177 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 1177's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-6.3%

1177

-4.8%

HK Pharmaceuticals

-4.6%

HK Market


1 Year Return

-28.8%

1177

-14.5%

HK Pharmaceuticals

5.2%

HK Market

Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: 1177 underperformed the Hong Kong Market which returned 5.2% over the past year.


Shareholder returns

1177IndustryMarket
7 Day-6.3%-4.8%-4.6%
30 Day-3.9%-8.5%1.0%
90 Day-17.7%-23.0%-10.9%
1 Year-28.0%-28.8%-13.4%-14.5%9.0%5.2%
3 Year27.1%23.6%-10.1%-15.7%10.5%-2.1%
5 Year188.8%176.3%48.7%33.6%29.9%6.5%

Long-Term Price Volatility Vs. Market

How volatile is Sino Biopharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sino Biopharmaceutical undervalued compared to its fair value and its price relative to the market?

29.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1177 (HK$6.36) is trading below our estimate of fair value (HK$9.07)

Significantly Below Fair Value: 1177 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1177's PE Ratio (9.9x) is in line with the Hong Kong Pharmaceuticals industry average.

PE vs Market: 1177's PE Ratio (9.9x) is in line with the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: 1177's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: 1177 is overvalued based on its PB Ratio (4x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is Sino Biopharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

-9.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1177's earnings are forecast to decline over the next 3 years (-9.5% per year).

Earnings vs Market: 1177's earnings are forecast to decline over the next 3 years (-9.5% per year).

High Growth Earnings: 1177's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 1177's revenue (12.2% per year) is forecast to grow slower than the Hong Kong market (12.3% per year).

High Growth Revenue: 1177's revenue (12.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (18.8%).


Past Performance

How has Sino Biopharmaceutical performed over the past 5 years?

21.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1177 has high quality earnings.

Growing Profit Margin: 1177's current net profit margins (39.5%) are higher than last year (10.4%).


Past Earnings Growth Analysis

Earnings Trend: 1177's earnings have grown significantly by 21.6% per year over the past 5 years.

Accelerating Growth: 1177's earnings growth over the past year (293.5%) exceeds its 5-year average (21.6% per year).

Earnings vs Industry: 1177 earnings growth over the past year (293.5%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 1177's Return on Equity (38.3%) is considered high.


Financial Health

How is Sino Biopharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 1177's short term assets (CN¥23.8B) exceed its short term liabilities (CN¥11.5B).

Long Term Liabilities: 1177's short term assets (CN¥23.8B) exceed its long term liabilities (CN¥13.6B).


Debt to Equity History and Analysis

Debt Level: 1177's debt to equity ratio (42.9%) is considered high.

Reducing Debt: 1177's debt to equity ratio has increased from 16.3% to 42.9% over the past 5 years.

Debt Coverage: 1177's debt is well covered by operating cash flow (39.9%).

Interest Coverage: 1177 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Sino Biopharmaceutical current dividend yield, its reliability and sustainability?

1.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1177's dividend (1.25%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.25%).

High Dividend: 1177's dividend (1.25%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.76%).


Stability and Growth of Payments

Stable Dividend: 1177's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1177's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (12.1%), 1177's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 1177's dividends in 3 years are forecast to be well covered by earnings (31.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average board tenure


CEO

Yi Li (59 yo)

1.08yrs

Tenure

CN¥22,896,000

Compensation

Mr. Yi Li serves as Chief Executive Officer and Executive Director at Sino Biopharmaceutical Limited since August 19, 2020. He joined J.P. Morgan China in October 2014 as chairman and chief executive offic...


CEO Compensation Analysis

Compensation vs Market: Yi's total compensation ($USD3.54M) is above average for companies of similar size in the Hong Kong market ($USD1.04M).

Compensation vs Earnings: Insufficient data to compare Yi's compensation with company performance.


Board Members

Experienced Board: 1177's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1177 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sino Biopharmaceutical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sino Biopharmaceutical Limited
  • Ticker: 1177
  • Exchange: SEHK
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$119.370b
  • Shares outstanding: 18.77b
  • Website: https://www.sinobiopharm.com

Number of Employees


Location

  • Sino Biopharmaceutical Limited
  • Office Tower
  • Unit 09, 41st Floor, Room 4109
  • Wan Chai
  • Hong Kong

Listings


Biography

Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It opera...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 10:01
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.